Johnson Financial Group, Inc. Abb Vie Inc. Transaction History

Johnson Financial Group, Inc.

$2.19 Billion
Q3 2024

A detailed history of Johnson Financial Group, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Johnson Financial Group, Inc. holds 37,931 shares of ABBV stock, worth $6.88 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares

37,931

Previous 36,908 2.77%

Holding current value

$6.88 Million

Previous $6.33 Million 18.33%

% of portfolio

0.34%

Previous 0.31%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$163.84 - $199.33 $167,608 - $203,914	1,023 Added 2.77%	37,931 $7.49 Million
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $1.37 Million - $1.61 Million	8,881 Added 31.69%	36,908 $6.33 Million
Q1 2024 May 14, 2024	SELL	$159.82 - $182.1 $142,719 - $162,615	-893 Reduced 3.09%	28,027 $5.1 Million
Q4 2023 Feb 09, 2024	SELL	$137.6 - $154.97 $138,425 - $155,899	-1,006 Reduced 3.36%	28,920 $4.48 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $18,569 - $21,496	139 Added 0.47%	29,926 $4.46 Million
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $428,272 - $532,956	-3,232 Reduced 9.79%	29,787 $4.01 Million
Q1 2023 May 12, 2023	BUY	$144.61 - $166.54 $244,390 - $281,452	1,690 Added 5.39%	33,019 $5.26 Million
Q4 2022 Feb 13, 2023	BUY	$138.31 - $165.87 $23,236 - $27,866	168 Added 0.54%	31,329 $5.07 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $1.2 Million - $1.38 Million	-8,937 Reduced 22.29%	31,161 $4.52 Million
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $181,658 - $230,947	-1,320 Reduced 3.19%	40,098 $6.14 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $207,604 - $257,578	-1,573 Reduced 3.66%	41,418 $6.71 Million
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $145,782 - $184,457	-1,357 Reduced 3.06%	42,991 $5.82 Million
Q3 2021 Nov 12, 2021	SELL	$106.4 - $120.78 $378,890 - $430,097	-3,561 Reduced 7.43%	44,348 $4.78 Million
Q2 2021 Aug 13, 2021	BUY	$105.21 - $117.21 $201,582 - $224,574	1,916 Added 4.17%	47,909 $5.4 Million
Q1 2021 May 14, 2021	BUY	$102.3 - $112.62 $218,308 - $240,331	2,134 Added 4.87%	45,993 $4.98 Million
Q4 2020 Feb 12, 2021	BUY	$80.49 - $108.67 $540,087 - $729,175	6,710 Added 18.06%	43,859 $4.7 Million
Q3 2020 Nov 12, 2020	BUY	$85.91 - $100.83 $230,926 - $271,031	2,688 Added 7.8%	37,149 $3.25 Million
Q2 2020 Aug 11, 2020	SELL	$73.37 - $98.18 $478,885 - $640,820	-6,527 Reduced 15.92%	34,461 $3.38 Million
Q1 2020 May 14, 2020	SELL	$64.5 - $97.79 $60,114 - $91,140	-932 Reduced 2.22%	40,988 $3.12 Million
Q4 2019 Feb 14, 2020	SELL	$72.13 - $90.25 $175,420 - $219,488	-2,432 Reduced 5.48%	41,920 $3.71 Million
Q3 2019 Nov 12, 2019	BUY	$62.98 - $75.72 $53,533 - $64,362	850 Added 1.95%	44,352 $3.36 Million
Q2 2019 Aug 09, 2019	BUY	$65.7 - $83.98 $319,039 - $407,806	4,856 Added 12.57%	43,502 $3.16 Million
Q1 2019 May 13, 2019	BUY	$77.14 - $90.79 $552,399 - $650,147	7,161 Added 22.74%	38,646 $3.12 Million
Q4 2018 Feb 11, 2019	SELL	$77.85 - $96.01 $475,429 - $586,333	-6,107 Reduced 16.25%	31,485 $2.9 Million
Q3 2018 Nov 09, 2018	BUY	$88.91 - $98.84 $1.27 Million - $1.41 Million	14,242 Added 60.99%	37,592 $3.56 Million
Q2 2018 Aug 07, 2018	SELL	$89.78 - $106.23 $519,377 - $614,540	-5,785 Reduced 19.86%	23,350 $2.16 Million
Q1 2018 May 07, 2018	SELL	$92.01 - $123.21 $141,051 - $188,880	-1,533 Reduced 5.0%	29,135 $2.76 Million
Q4 2017 Feb 12, 2018	SELL	$89.56 - $98.21 $46,212 - $50,676	-516 Reduced 1.65%	30,668 $2.97 Million
Q3 2017 Nov 09, 2017	BUY	$69.85 - $89.22 $2.18 Million - $2.78 Million	31,184	31,184 $2.77 Million

Others Institutions Holding ABBV

# of Institutions

3,849

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $321B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Johnson Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Johnson Financial Group, Inc. with notifications on news.

Account

Johnson Financial Group, Inc. Abb Vie Inc. Transaction History